形态学诊断为急性早幼粒细胞白血病儿童的遗传学与临床特征
该研究对111例形态学诊断为急性早幼粒细胞白血病(APL)的儿童进行二代测序分析,在120份诊断与复发期DNA样本中检出95例RARA重排(94例PML-RARA、1例NPM-RARA)及2例KMT2A重排。13份无RARA重排的RNA样本中发现CPSF6-RARG、NPM1-CCDC28A、TBC1D15-RAB21各1例及TBL1XR1-RARB融合2例。有RARA重排者生存明显优于无RARA重排者,后者更合理分类为AML亚类而非APL。
要点
- 形态学诊断APL儿童中多数可检出RARA重排,但部分无RARA重排者存在其他融合基因。
- 无RARA重排者检出CPSF6-RARG、NPM1-CCDC28A、TBC1D15-RAB21、TBL1XR1-RARB等融合。
- 有RARA重排的APL生存明显优于无RARA重排者。
核心结论
- 形态学诊断为APL但无法鉴定出RARA重排的患者,更合理分类为AML的亚类而非APL,应根据遗传学异常考虑个体化治疗。
研究设计与样本
- 对111例形态学诊断为APL的儿童患者进行二代测序全面变异分析。
- 对120份诊断期和复发期DNA样本进行结构变异分析。
- 对13份诊断期无RARA重排的RNA样本进行融合基因分析。
- 对77例RARA重排儿童(80份样本)进行单核苷酸变异分析。
主要发现
- 120份DNA样本中95份检出RARA重排(94份PML-RARA、1份NPM-RARA),2份检出KMT2A重排。
- 13份无RARA重排的RNA样本中检出CPSF6-RARG、NPM1-CCDC28A、TBC1D15-RAB21各1例,TBL1XR1-RARB融合2例。
- 77例RARA重排儿童中FLT3、WT1、USP9X、NRAS、ARID1A呈复发性改变,WT1是复发APL中唯一复发性突变基因。
- 17份无RARA重排的原发样本中WT1、NPM1、NRAS、FLT3、NSD1呈复发性突变,9份复发样本中WT1、NPM1、TP53、RARA呈复发性突变。
- 有RARA重排的APL生存明显优于无RARA重排者。
临床怎么用
- 作者认为,形态学诊断为APL但无法鉴定出RARA重排的患者更合理分类为AML亚类而非APL。
- 作者认为,应根据遗传学异常考虑个体化治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q22;q21), resulting in a PML-RARA fusion that is the master driver of APL. A few cases that cannot be identified with PML-RARA by using conventional methods (karyotype analysis, FISH, and RT-PCR) involve abnormal promyelocytes that are fully in accordance with APL in morphology, cytochemistry, and immunophenotype. To explore the mechanisms involved in pathogenesis and recurrence of morphologically diagnosed APL, we performed comprehensive variant analysis by next-generation sequencing in 111 pediatric patients morphologically diagnosed as APL. Structural variant (SV) analysis in 120 DNA samples from both diagnosis and relapse stage identified 95 samples with RARA rearrangement (including 94 with PML-RARA and one with NPM-RARA) and two samples with KMT2A rearrangement. In the eligible 13 RNA samples without any RARA rearrangement at diagnosis, one case each with CPSF6-RARG, NPM1-CCDC28A, and TBC1D15-RAB21 and two cases with a TBL1XR1-RARB fusion were discovered. These uncovered fusion genes strongly suggested their contributions to leukemogenesis as driver alternations and APL phenotype may arise by abnormalities of other members of the nuclear receptor superfamily involved in retinoid signaling (RARB or RARG) or even by mechanisms distinct from the formation of aberrant retinoid receptors. Single-nucleotide variant (SNV) analysis in 77 children (80 samples) with RARA rearrangement showed recurrent alternations of primary APL in FLT3, WT1, USP9X, NRAS, and ARID1A, with a strong potential for involvement in pathogenesis, and WT1 as the only recurrently mutated gene in relapsed APL. WT1, NPM1, NRAS, FLT3, and NSD1 were identified as recurrently mutated in 17 primary samples without RARA rearrangement and WT1, NPM1, TP53, and RARA as recurrently mutated in 9 relapsed samples. The survival of APL with RARA rearrangement is much better than without RARA rearrangement. Thus, patients morphologically diagnosed as APL that cannot be identified as having a RARA rearrangement are more reasonably classified as a subclass of AML other than APL, and individualized treatment should be considered according to the genetic abnormalities.
引用
- Zhao J, Liang JW, Xue HL, et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia. 2018. PMID: 30575821. doi:10.1038/s41375-018-0338-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。